Hepatitis C virus (HCV) is a common infection of the liver with high medical costs. It’s a public health concern worldwide. While there is a high cost for using direct-acting antivirals for HCV treatment, eliminating the disease reduces the cost burden. This paper discusses our study to estimate the costs, savings and timeline associated with the elimination of HCV. Our paper includes the following sections:
- Background: Overview and the elimination of HCV
- Study results, including timeline and projected costs for HCV elimination
- Discussion, including HCV incidence trends, transmission, and barriers to elimination
This paper was commissioned by Gilead Sciences, Inc.